|
業務類別
|
Biotechnology |
|
業務概覽
|
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector). |
| 公司地址
| 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608 |
| 電話號碼
| +1 510 505-2680 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.4dmoleculartherapeutics.com |
| 員工數量
| 196 |
| Mr. Scott Bizily, J.D.,PhD |
Chief Legal and Corporate Secretary |
-- |
28/04/2026 |
| Dr. Fariborz Kamal, PhD |
Chief Operating Officer |
美元 551.74K |
07/01/2026 |
| Mr. Christopher Paul Simms |
Chief Commercial and Business Officer |
-- |
28/04/2026 |
| Mr. Ashoo Gupta |
Principal Accounting Officer, Controller and Vice President, Finance |
-- |
18/03/2026 |
| Mr. David Kirn, M.D. |
Director, President and Chief Executive Officer |
美元 667.25K |
07/01/2026 |
| Mr. Kristian F. Humer |
Chief Financial Officer |
美元 66.00K |
30/03/2026 |
|
|
| Ms. Susannah Gray, M.B.A. |
Independent Director |
28/04/2026 |
| Dr. Charles P. Theuer, M.D.,PhD |
Independent Director |
28/04/2026 |
| Dr. John F. Milligan, PhD |
Executive Chairman of the Board |
28/04/2026 |
| Mr. Glenn P. Sblendorio |
Director |
07/01/2026 |
| Ms. Nancy Miller-Rich |
Independent Director |
28/04/2026 |
| Mr. Jacob M. Chacko, M.B.A.,M.D. |
Independent Director |
28/04/2026 |
| Mr. David Kirn, M.D. |
Director, President and Chief Executive Officer |
07/01/2026 |
| Ms. Shawn Cline Tomasello, M.B.A. |
Independent Director |
28/04/2026 |
|
|
|
|
